This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Oncolytic Viruses / Non-viral Gene Therapy Delivery
November 30 - December 1, 2022
Digital Conference8:00AM EST // 1:00PM GMT // 2:00PM CET

Johanna Kaufmann
Executive Vice President for Oncology at Codagenix Inc., USA


Dr. Kaufmann is a scientific and strategic leader in immuno-oncology with broad expertise across preclinical and translational drug development. Before joining Codagenix, she was a Scientific Director at GSK, leading an immune biology group and supporting progression of multiple portfolio assets as part of the immuno-oncology senior leadership team. She previously led mechanisms of action studies for immuno-oncology assets at TESARO and headed three preclinical herpes virus vaccine programs at Genocea Biosciences. Dr. Kaufmann earned a MS in Molecular Medicine from Friedrich-Alexander University in Erlangen, Germany, and a PhD in Cancer Virology from the German Cancer Research Center (DKFZ) and Heidelberg University, Germany.

Agenda Sessions

  • The Codon-Modified Virotherapeutic CodaLytic™ Modulates the Tumor Microenvironment in Models with Different Immune Contextures